WHO Technical Meeting on Piloting RSV Surveillance
based on the Global Influenza Surveillance and Response System

28-30 June 2016
InterContinental Hotel, Geneva, Switzerland
Executive summary

Respiratory syncytial virus (RSV) is an important viral respiratory pathogen, causing acute, sometimes fatal lower respiratory tract infections in infants and young children. In addition, RSV contributes substantially to severe morbidity in the elderly. With significant and rapid progress in the development of RSV vaccine, it is expected that a RSV vaccine would become available in the next few years. There is a need to develop a global surveillance platform to serve as evidence base including a better understanding of the epidemiology, seasonality, high risk groups and circulation of the RSV.

The WHO Global Influenza Programme (GIP) is in the process of implementing a pilot of RSV surveillance based on the influenza surveillance platform, the WHO Global Influenza Surveillance and Response System (GISRS). The aim of the pilot is to test the feasibility of building on the capacities of GISRS, an established, well-functioning and long-term network, where many countries already collect and test samples, for targeting RSV.

Two meetings, in March 2015 and in February 2016, brought together experts from the scientific communities of RSV and influenza. The first meeting was an informal consultation on RSV surveillance leading to a strategic plan proposal for global RSV surveillance. The second one was an expert working group meeting that focused on the agreement of structures and component details of an RSV pilot. This included discussions on case definitions, strategies for case selection, laboratory protocols for RSV detection, and data collection and reporting procedures.

A third meeting was held in June 2016 in Geneva wherein 14 selected countries agreed on the strategies and operational elements to roll-out the RSV pilot surveillance by the end of 2016. Countries presented their existing surveillance methodologies and agreed upon changes that were needed in case definitions and selection, need to test at least 1000 respiratory specimens per year, targeted sampling of infants and under-five age group, year-round sampling, laboratory testing, data management and case-based reporting required to roll-out the RSV pilot. The pilot is planned for 3 years in 2 or 3 countries in each WHO region. Two documents, the WHO surveillance guidance for the RSV pilot, and Instructions for use of the CDC real-time RT-PCR assay for RSV were finalized at this meeting. The potential role of reference laboratories was defined, testing protocols validated, and algorithms for selection cases for specimen collection was developed. The minimum dataset for collection was defined, the need for case-based data, reporting periodicity and platforms was agreed upon. It was agreed that each country develops a detailed manual that could be referred to by the participating sentinel site to ensure that all sites use a consistent methodology. Each country would ensure training of all the participating sentinel sites at the start of the pilot that would focus on the selection and testing of cases, completing the forms, laboratory protocols and timely reporting.

As participating countries enlist and train sentinel sites, train laboratory staff in testing protocols, participate in proficiency tests, concurrent efforts have been initiated to expand the FluMart platform to include case-based RSV surveillance information.
Meeting Report

Background

Respiratory syncytial virus (RSV) is an important viral respiratory pathogen, causing acute, sometimes fatal acute lower respiratory tract infections in infants and young children. Re-infections are common and occur in all age groups. In children below the age of 5, the RSV burden of disease exceeds the burden of disease from influenza and other respiratory viral agents. RSV disease is known to occur in the elderly and in adults with chronic medical conditions (such as COPD) but the global disease burden is not well known. At present there are several RSV vaccine trials underway, of which one is in phase 3. With the expectation that RSV vaccines may become available in a few years time, there is a need for RSV surveillance data. RSV surveillance data will provide baseline data on the epidemiology and seasonality of RSV in different parts of the world. It will help define to what extent severe RSV disease in certain age and risk groups is a health priority.

The WHO Global Influenza Programme (GIP) is in the process of developing a pilot study of RSV surveillance based on the influenza surveillance platform, the WHO Global Influenza Surveillance and Response System (GISRS). The advantage of using the GISRS is that one can build from an established, well-functioning network, where many countries already collect and test samples for RSV. There are links to national policy makers and there is the potential to understand influenza and RSV together. The GISRS is considered to be the most efficient and effective platform to pilot test RSV surveillance.

Two previous RSV meetings, in March 2015 and in February 2016, were held to bring together experts from the fields of RSV and influenza. The first meeting was an informal consultation on RSV surveillance leading to a strategic plan proposal for global RSV surveillance. The second one was an expert working group meeting and focused on the agreement of structures for an RSV pilot. This included the discussion of suitable case definitions, identification of strategies for case selection, agreement on the optimal laboratory methods for RSV detection, and identification of the best data collection and reporting procedures.

The next step is to launch the pilot of RSV surveillance. The meeting objective of this 3rd meeting, held in June 2016, was therefore to reach a common understanding to facilitate implementation of RSV pilot surveillance after the meeting and get countries ready for implementation. Since the meeting in February, two documents were further developed: 1) the WHO surveillance guidance for the RSV pilot, and 2) Instructions for use of the CDC real-time RT-PCR assay for RSV. At the meeting the group aimed to reach consensus on the strategies and operational elements for piloting RSV surveillance in the selected countries.

The roll-out of the pilot is planned for 3 years in 2 or 3 countries in each WHO region. Selected countries are:

AFR: Côte d’Ivoire (CI), Mozambique (MOZ), South Africa (SA)
AMR (PAHO): Argentina (ARG), Brazil (BRA), Chile (CHI)
EMR: Iran (IRA), Oman (OMA), Egypt (EGY)
EUR: Germany (GER), Russia (RUS)
SEAR: India (IND), Sri Lanka (SRL)
WPR: Cambodia (CAM), Mongolia (MON)

In addition, three laboratories with extensive experience in RSV diagnostics and research have agreed to provide support to the pilot laboratories. These three laboratories are:
- The Centers for Disease Control and Prevention (CDC), Atlanta GA, USA;
- The laboratory of Public Health England (PHE), London, UK;
Objectives pilot RSV surveillance

The primary objectives of the RSV pilot are to:
- Assess the suitability and feasibility of RSV surveillance based on the GISRS platform
- Identify RSV seasonality in different countries and regions
- Determine the age and/or risk groups for severe RSV disease
- Evaluate RSV case definitions and sampling strategies
- Provide improved knowledge on RSV healthcare burden
- Assess feasibility of using the FluNet and FluID for data reporting
- Build laboratory capacity for RSV testing in pilot countries
- Standardize laboratory procedures for RSV detection and quality assurance
- Document possible negative impact on existing influenza surveillance
- Report surveillance data to raise awareness and provide evidence to inform policy decisions

Secondary objectives have also been defined and include:
- the assessment of the additional costs incurred through implementation of RSV surveillance
- provide a platform for future RSV studies (such as vaccine effectiveness studies, cost effectiveness studies; assess efficacy of RSV treatment strategies, and bank samples i.e. evolution of strains over time and relation to vaccine strains).

The RSV pilot will not provide the following: data on population-based RSV disease burden, data which can be used to assess RSV vaccine effectiveness, data on economic burden of RSV, and data which will give a complete and detailed clinical description of RSV disease in all age and at-risk groups.

Epidemiological aspects of RSV surveillance

The guidance document for RSV surveillance contains important information to perform RSV surveillance in pilot countries. Information on the case definitions to be used for different age groups is included, as well as minimum criteria for the number of samples to be collected per year and pilot country, and the sampling strategy. Another aspect is year-round data collection in order to define the seasonality. The RSV surveillance should be primarily hospital-based. The reason for this is that when RSV vaccines become available they will primarily aim at preventing severe cases, i.e. case that require hospital treatment. The pilot includes all age groups since although RSV burden is mainly associated with young children there is also a significant disease burden that is not well understood nor recognised in older age groups.

There are several challenges in using the GISRS platform for RSV surveillance. There is the need for modified case definitions, enhanced recruitment in the very young age group (first few months of life) and year round testing. In order to collect surveillance data on specific groups for policy and programme purposes (young children and elderly), it is important to collect a minimum quota of samples in 4 distinct age groups (0-<6m; 6-59m; 5-64 years; ≥65 years). Finally, there is a need to collect additional data which may be challenging as this potentially may have a negative effect on the current GISRS. A balance must be found between making the least changes to flu surveillance, but at the same time still providing valid RSV data. The pilot will help to identify how this is best achieved.

The RSV hospital surveillance case definition is based on SARI as defined in existing GISRS influenza surveillance. However, the RSV “extended SARI” case definition will also include patients of all ages who do not have fever or history of fever but otherwise meet the SARI case definition. In addition to
this extended case definition additional criteria have been included for infants 0-6 months of age: apnea and/or sepsis. This is because RSV disease may present with other symptoms in young infants.

The defined sampling strategy is that at least 20 cases/week should be recruited and tested so that all pilot sites can describe the RSV seasonal pattern. These cases should also be recruited in order to meet age groups quotas. More details on the specific requirements can be found in the surveillance guidance document.

For the pilot project the sampling strategy should be well documented and sites should be chosen to ensure that the minimum sample sizes are achieved. This should include, where possible, both in-patient wards (adult general medical and specialist medical; respiratory/infectious disease; and pediatric) and intensive care units (ICU) (both adult, pediatric and neonatal care).

At the meeting each pilot country presented their implementation plan for RSV surveillance and identified challenges and actions to be taken in the application of the proposed RSV case definition, ensuring an adequate number of samples in particular from the youngest age group, and ensuring all-year round surveillance.

External advisors highlighted that there is a need to track whether local or national ALRI case definitions change over time in order to interpret results and that the collection of clinical data is an opportunity to assess case definitions. Furthermore, for the 5-64 age group, there was a plea to reconsider increasing the (low) priority given to data on RSV in pregnant women as this may be relevant for the maternal vaccination. This target group could be included in surveillance by giving priority to recruitment in female wards. However, it was recognised that to study this issue properly special studies may also be required. Regarding the interpretation of seasonality data, special care is needed when data are coming from widely dispersed sites with a wide latitude range (since seasonality may vary across these sites and this information may be lost when pooling data).

Following the country presentations, the participants were divided into 3 working groups and discussed the challenges in the epidemiological data collection, changes required in existing reporting systems and actions that need to be taken.

From the group work the following points were made:

Site selection and quotas:
• It is important to record descriptive information about the recruitment site settings in the pilot as case characteristics may vary by type of facility;
• There is a need for information on the surveillance site setting (urban/rural, socio-economic status, pollution levels, climate/seasons; type of wards included in surveillance);
• It was proposed to introduce the extended case definition in a limited number of sites to assure high quality of data collected;
• The defined quotas for the age groups pose a challenge. It is difficult to recruit older adults, as many SARI cases in this age group are not admitted to hospital. For the very young it will be a challenge to recruit the most sick/or youngest (0-2 month) age group as clinicians may be resistant.
• It was highlighted that the predefined quotas are per country. This is a minimum and countries can opt to increase this, especially during the RSV season.

Year round surveillance, sampling strategy and data reporting:
• The working groups acknowledged the need to do year-round surveillance. Some countries were concerned about recruitment and sampling cases outside the RSV season. However, it is important to perform this in the pilot phase in order to identify the seasonality and possible year-to-year variation.
• The focus on hospital surveillance with extended SARI case definition was generally accepted.
The strength of this pilot is that all participating countries will use a common approach. This means that countries will not just test influenza negative samples for RSV, as this will create unacceptable bias; and will not just test SARI cases, as this will miss many or even most RSV cases. Adoption of the extended SARI case definition will increase recruitment and help achieve sample quotas.

- Case-based data will be collected from all cases (all tested cases; either negative or positive) that meet the extended case definition.

There was general recognition of the importance of training of staff in application of the extended case definitions, sampling procedures and completion of the new/adapted forms. There is also a need to assess the number of cases meeting the SARI and extended SARI case definitions and look at the performance of different case definitions in sites.

For the future of the project, we will need to understand what evidence is required for policy making groups to make decisions and align with this. Ongoing RSV surveillance may not be needed at the same scale and intensity as influenza as several years of hospital data will be available for policy makers, and the RSV virology is less dynamic than influenza.

While the countries generally expect to be able to meet the required criteria, a few countries indicated that additional staff and/or funding is required and training needs to be provided. WHO HQ requested for each country to provide details of essentials costs to be covered by the project.

Finally, a few countries indicated that they have only recently been invited to participate in the pilot of RSV surveillance and discussions need to be continued at their institutes.

Laboratory aspects of RSV surveillance

For the RSV pilot it is important to standardize the laboratory procedures for RSV detection and assure the quality of the methods used. In addition, this work will help to improve laboratory capacity, define the role of RSV reference laboratories and provides a platform for future RSV studies.

The guidance document contains information on the type of specimens to be used, procedures on the transport and storage and testing algorithm. The agreed method to use is real-time RT-PCR, this can be an in-house method or the CDC assay. Samples can be tested real-time—simultaneously RSV and influenza testing upon arrival in the laboratory, or in batches, e.g. once a week. The testing strategy can be defined by the countries according to available resources. For internal quality assurance laboratories need to maintain and document rigorous internal quality control measures. For external control a proficiency panel will be distributed at the start of the pilot.

The CDC RSV real-time RT-PCR assay was introduced, as well as the proficiency panel and Material Transfer Agreement (MTA). Instructions for use of the CDC RSV assay are available in a separate document and were disseminated to all participants. The CDC will also provide a panel for proficiency testing as part of the external quality control assessment (EQA). All laboratories will need to complete the MTA form and send it back to CDC. As soon as the paperwork is completed, the materials (CDC assay(s), positive control, and RSV EQA) are shipped. The expected timeline for this is August 2016. The laboratory will need to test the proficiency panel with their in-house method and the CDC assay and send back the results to CDC. If the performance of the in-house methods is good, they can continue to use this method during the pilot. If the performance is not sufficient, the countries should use the CDC assay. WHO HQ will arrange the logistics of the shipping from and to the reference laboratories, and CDC can make enzymes and extraction kits available for 1000
samples per country though IRR. If a country is not yet registered with IRR this should be done immediately.

On day 2 of the meeting, the laboratory side of the pilot RSV surveillance was discussed. Following the presentations on laboratory aspects and role of RSV reference laboratories, 3 working groups discussed the implementation of the RSV testing algorithm. Most countries are ready to make adjustments for RSV testing. Generally, countries expect to do batch testing weekly; with a few stating that fortnightly is more realistic. Few countries indicated to plan to test their negative samples for RSV, but they were highly encouraged to test all samples collected for RSV irrespective of the influenza test result.

Additional group comments related to the laboratory aspects were:

- Some countries expressed concern about the storage of samples; there may be limited space in freezers. It was not decided how long the specimens should be stored. In case of limited space, the storage could be limited to positive samples;
- Subtyping and sequencing of positive samples will need further discussion with the reference laboratories. Subtyping is not planned for the 1st pilot year, but may be done later on;
- Need for guidance on what level of positivity (% positive) countries may expect with the extended case definitions;
- Regarding the reporting back of results to the sentinel sites, it was advised to use the same procedures are used in influenza surveillance;
- The need for training needs to be assessed after results are available after the proficiency testing.
- If a country performs routine testing with methods additional to real-time PCR this will be an opportunity to identify sensitivity problems (an example was IFAT testing done parallel with PCR, and they found mismatches of primers and probes with loss of sensitivity with some of the circulating strains in the multiplex PCR).
- Information on timing of receipt of specimen in the laboratory and the conditions (e.g. whether the sample was received at the correct temperature) could be part of the internal quality control of the laboratory.

All comments were taken into consideration and the surveillance guidance has been updated accordingly. The first steps in the pilot will be the distribution of the proficiency panel and primer kits in August 2016.

In addition to the CDC in Atlanta, there are two specialized laboratories that can serve as an RSV reference laboratory: Respiratory Virus Unit - Public Health England (HPE) in London, and the National Institute for Communicable Disease (NICD) in Johannesburg. They presented the various activities being carried out in the reference laboratories. The PHE laboratory can provide a PCR protocol for RSV detection and provide support as necessary to participating laboratories. The collaborating centre from Melbourne may also have potential to function as an RSV reference laboratory in the future, but their focus so far has been on influenza surveillance and a research program on RSV (ferret model). The influenza reference laboratories have several activities beyond supplying reagents and probes and they need to decide which activities are suitable for RSV; the roles and responsibilities need to be defined.

Data reporting

On day 3 the data reporting procedures were presented and discussed. Influenza surveillance data can be reported through a web-based data collection platform (FluMart); virological data being reported to FluNet and epidemiological data to FluiD. RSV data reporting can be integrated into this system. There are flexible data input options and data can be case-based or aggregated (e.g. in excel or csv files export files that can be uploaded). The collection of case-based data will only be done during the pilot phase to be able to validate the case definitions and do a more in depth analysis of the cases under surveillance. The patient ID can be defined by the country, but needs to be unique in
the country dataset. WHO HQ will add a country code to differentiate between different ID numbers. Updates will be done by the upload of changed information, a new ID means a new patient. The variables to be included in the reporting are on the case report form. Countries can use their own form, but would need to assure that all variables are included. An excel file with an explanation of all variables is available. The group discussed the best ways to enter the laboratory and epidemiological data. Case-based data are requested to be uploaded on a weekly basis preferably (every two weeks is also an option for some countries) in one upload – but if not feasible the epi and lab data can be uploaded at different time intervals as long as the patient ID is included on each case report to allow data linkage. Finally, it is important to assure completeness of the variables collected.

The available web-based system has opportunities to present the data in specific outputs. The outputs can be used to characterize severe RSV infection in mainly hospitalized cases and present trends by country, age groups and possible RSV subtype. Country graphs can be made showing the number of RSV positive cases by age group over time. Questions that need to be answered are how the data are secured and documented and who has access to the data. It was agreed that data should be shared with the pilot countries only at this stage.

**Monitoring and evaluation of the RSV pilot**

The quality of the data collected is important and should be monitored and maintained on a continuous basis. A standardized set of monitoring indicators and documentation will help to analyse the capacity levels. There are different aspects in monitoring the quality of a surveillance system: accuracy, completeness, timeliness, relevance, consistency across data sources and reliability. Monitoring should occur at different levels: site level, laboratory and reporting (on country level) and internationally by the Regional reference laboratories and WHO. The key aspect is the quality of the data and monitoring at the sentinel site level. At the surveillance site the quality of the data, completeness and reporting impacts all future analyses and outputs.

At the surveillance site, the following need to be monitored: completeness of the case forms and check for correctness, number of specimens collected weekly, “denominator” data, appropriate distribution of samples, proper collection of specimens, labelling and storage. At the national level, monitoring is performed by proficiency testing and samples received from sites need to be checked for quality. It is important to include controls in the assay and record the results, monitor CT values of RSV and RNP. Furthermore, the balance of specimens by the 4 age groups (25% each) needs to be checked on a weekly basis to assure the minimum samples that need to be collected for the country (aggregated from sites), the denominator needs to be monitored from each site, timeliness of sample processing needs to be checked and finally the timely and complete weekly reporting to WHO needs to be assured.

For the internal quality control assurance checklists for the site level and the laboratory can be used. It was emphasized that early monitoring is very important to make sure the forms are completed and targets are met. It is therefore suggested to do these checks regularly at the start of the pilot. Initially this should be monitored weekly, later on this may be changed to monthly. Similarly, early monitoring is needed to assure laboratory quality standards are followed. Additional data should be collected on the total number of extended SARI cases, total hospital admissions and total number of hospital admission for respiratory disease in hospital surveillance sites. It was however noted that these data may not be possible to collect in all sites. Finally, to track the impact of the program information should be collected on additional costs (staff time, reporting time, funding). Finally, issues/challenges related to the pilot and impact on flu surveillance should be documented as part of the monitoring program.
Based on the different quality aspects (accuracy, completeness, timeliness, etc.), indicators should be defined: e.g. score of proficiency testing, % of forms with complete data, % of weeks data reported, time from receipt to test report. An easy way of presenting the output is a stacked bar chart of samples collected by age group for the pilot countries, and monthly country aggregate by age and number of samples.

After the first pilot year, the case definitions will be analysed, the RSV seasonality for the different countries will be defined, and data age and risk groups will be available. Additionally, the feasibility of using the influenza platform for RSV will be evaluated. To achieve this data quality assurance of the systems is essential.

Next steps of roll-out of pilot of RSV surveillance and way forward

After the meeting the selection of sentinel sites will be confirmed and training for the sites needs to be arranged. For the laboratory side the preparation and logistics for the sampling and testing will take place, with the distribution of proficiency test and primer kits planned for August. Sample collection and testing is planned as of October. Following this meeting the existing data system needs to be checked and prepare for reporting in Oct-Nov.

The exact indicators need to be defined to assure standardisation across sites; a group needs to develop this in detail to include it the overall guidance. A training manual will be needed for all sites with standardisation of methods with focus on how to select the cases, collect the samples and complete the form. In addition a series of monitoring endpoints that can be built in the system is needed.

Finally, in the coming period WHO will make sure communication is maintained between the pilot laboratories, the reference laboratories, external groups (e.g. governments and donors) and other stakeholders.

Regarding funding there is some budget available from the Bill and Melinda Gates Foundation, but this will not cover additional work. Additional support comes from other global sources and from governments; for longer term support will be needed from government public health budgets and possibly partnerships with influenza and other initiatives.

All different aspects important for the RSV surveillance pilot were presented and challenges were discussed. By finalizing the protocols and getting the laboratories and doctors ready for testing, the RSV pilot will be rolled-out in October 2016.
WHO Technical Meeting on Piloting RSV Surveillance based on the Global Influenza Surveillance and Response System

InterContinental Hotel, Geneva, Switzerland
28 to 30 June 2016

Provisional Agenda

Chairs: H. Campbell and S. Broor

Tuesday, 28 June 2016

09:00 – 09:30  Opening and welcome
W. Zhang
Background and introduction
Disclosure of interest declared by experts
Selection of Chairs and appointment of Rapporteur

09:30 – 09:40  Meeting objectives and expected outcomes
T. Besselaar

09:40 – 09:55  Summary of the previous WHO Expert Working Group Meetings on RSV Surveillance based on the GISRS Platform
T. Ziegler

09:55 – 10:10  Overview of the preparations and work done since February 2016
S. Jackson

Session 1: RSV Pilot – Epidemiological Surveillance

10:10 – 10:40  Introduction of the WHO RSV surveillance guidance for pilot: epidemiological aspects
H. Campbell

10:40 – 11:10  Coffee break and group photo

11:10 – 11:15  Introduction to group work
S. Gerber

11:15 – 12:20  Working Groups - Implementation of the epidemiological aspects of RSV surveillance
Group leaders:
Gr1: S. Gerber
Gr2: C. Tecu
Gr3: J. Moyes

12:20- 13:20  Lunch

13:20- 15:05  Country presentation on implementation plan of RSV surveillance - epidemiological aspects (15 min per country)
- Iran
- Oman
- Germany
- Russia
- South Africa
- Cote d’Ivoire
- Mozambique

15:05 – 15:25  Coffee break
15:25 – 17:10  
- *Continued:* Country presentations on implementation plan of RSV surveillance - epidemiological aspects (15 min per country)  
  - Brazil  
  - Chile  
  - Argentina  
  - Mongolia  
  - Cambodia  
  - Egypt  
  - India

17:10-17:40  
Plenary discussion – Implementation of the epidemiological aspects of RSV surveillance in pilot countries  
**Facilitator:** H. Campbell

17:40  
*Closure of day 1*

**Wednesday, 29 June 2016**

09:00 – 09:10  
Review of outcomes from Day 1  
**H. Campbell**

**Session 2: RSV Pilot – Laboratory Surveillance**

09:10 – 09:25  
Introduction of the WHO RSV surveillance guidance for pilot: laboratory aspects  
**S. Jackson**

09:25 – 10:30  
Presentation of capacity and potential support from RSV reference laboratories:  
- Centre for Disease Control and Prevention (CDC)  
  (RSV real-time RT PCR protocol)  
**T. Peret**

10:30 – 10:50  
*Coffee Break*

10:50 – 11:20  
- Public Health England (PHE)  
  **J. Ellis**

11:20 – 11:50  
- The National Institute for Communicable Diseases (NICD)  
  **F. Treurnicht**

11:50 – 12:30  
Discussion of roles of RSV reference laboratories  
**Facilitator:** J. Ellis

12:30 – 13:30  
*Lunch*

13:30 - 13:35  
Introduction to group work  
**S. Broor**  
*Group Leads:*  
Gr1: S. Broor  
Gr2: F. Treurnicht  
Gr3: J. Ellis

13:35 – 15:30  
Working groups – Implementation of the RSV testing algorithms  
**Group Leads:**  
Gr1: S. Broor  
Gr2: F. Treurnicht  
Gr3: J. Ellis

**(Coffee Break 20 min)**

15:30 – 16:30  
Working groups reporting back and discussion  
**Facilitator:** F. Treurnicht
16:30 – 17:30 Plenary discussion – other laboratory aspects aside from testing algorithms
Facilitator T. Ziegler
17:30 Closure of day 2

Thursday, 30 June 2016

09:00 – 09:10 Review of outcomes from Day 2 S. Broor

Session 3: RSV Pilot – Data Reporting

09:10 – 09:30 Introduction of laboratory and case based data fields for reporting J. Fitzner
09:30 – 09:45 Presentation of proposed RSV surveillance outputs S. Hirve
09:45 – 10:05 Discussion on RSV data fields, reporting and surveillance outputs Facilitator H. Campbell
10:05 - 10:30 Demonstration of electronic data transfer onto FluMart J. Fitzner
10:30 -10:50 Coffee Break
10:50 – 10:55 Introduction to working groups J. Moyes
10:55 – 11:50 Working groups – Implementation of RSV data reporting – actions in countries Group leads:
Gr1: S. Gerber
Gr2: C. Tecu
Gr3: J. Moyes
11:50- 12:35 Working groups reporting back
- Group 1
- Group 2
- Group 3

12:35 – 13:35 Lunch

Session 4: Way Forward

13:35 – 14:00 Influenza- Monitoring and evaluation experience and its potential application to RSV surveillance A. Moen
14:00 – 14:20 Discussion on proposed monitoring and evaluation of the pilot of RSV surveillance Facilitator E. Simoes
14:20 – 14:40 Coffee Break
14:40 – 15:10 Discussion on practicalities of the pilot of RSV surveillance Facilitator S. Gerber
<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:10 – 15:45</td>
<td>Next steps of roll-out of pilot of RSV surveillance</td>
<td>W. Zhang</td>
</tr>
<tr>
<td>15:45 - 16:15</td>
<td>Summary of the meeting</td>
<td>Chairs</td>
</tr>
<tr>
<td>16:15 – 16:20</td>
<td>Closing</td>
<td>W. Zhang</td>
</tr>
<tr>
<td>16:20</td>
<td>Closure</td>
<td></td>
</tr>
</tbody>
</table>
List of Participants

Hanan Al Kindi, Central Public Health Laboratories, Muscat, Oman
Idris Saleh Al-Albaidani, Department of Communicable Diseases, Ministry of Health, Oman
Tamin Azaibi, Respiratory Virus Immunology Team, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, USA
Darmaa Badarch, Virology laboratory, Infectious Diseases Surveillance Department (IDSD), National Center for Communicable Diseases (NCCD), Ulaanbaatar, Mongolia
Elsa Baumeister, Jefa Servicio Virosis Respiratorias, Centro Nacional de Influenza de OPS/OMS, Departamento de Influenza, Buenos Aires, Argentina
Shobha Broor, Gurgaon (Haryana), India
David Brown, Laboratorio de Virus respiratorios e do Sarampo, Pavilhao Helio e Peggy Pereira, Brazil
Silke Buda, Department of Infectious Disease Epidemiology, Berlin, Germany
Harry Campbell, Centre for Population Health Sciences, The University of Edinburg, Edinburgh, UK
Narciso Cardoso, Biólogo e Epidemiologista, Direcção Nacional de Saúde Pública, Mozambique
Mandeept Chadha, National Institute of Virology, Indian Council of Medical Research, Ministry of Health and Family welfare, Pune, India
Darapheak Chau, Quality Assurance Unit, Cambodia
Savuth Chin, Virology Unit, Institut Pasteur in Cambodia, Cambodia
Joanna Ellis, Clinical Scientist Respiratory Virus Unit, Virus Reference Department, London, UK
Mostafa Elnawawy, Virology Laboratory, Central Public Health Laboratory (CPHL), Ministry of Health and Population, Department of Virology, Egypt
Rodrigo Fasce, National Influenza Center, Ministry of Health and Medical Education, Santiago, Chile
Susan Gerber, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, USA
Iris Hasibra, Institute of Public Health, Tirana, Republic of Albania
Hervé Kadjio, National Influenza Center (NIC), Institut Pasteur de Côte d'Ivoire, Abidjan, Cote d'Ivoire
Tamara Meerhoff, Radboud University Medical Center, Nijmegen, The Netherlands
Ann Moen, Influenza Branch, Centers for Disease Control and Prevention (CDC), Atlanta, USA
Jocelyn Moyes, National Institute for Communicable Diseases, Centre for Respiratory Diseases and Meningitis (Virology) NICD, Sandringham, South Africa
James Nokes, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Dulmaa Nyamkhhuu, National Center for Communicable Diseases, Mongolia
Teresa Peret, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, USA
Maria Pisareva, Research Institute of Influenza, Russian Academy of Medical Sciences, National Influenza Center, Russian Federation
Patrick Reading, WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
Brunhilde Schweiger, National Influenza Reference Center, Berlin, Germany
Eric Simoes, Center for Global Health, Aurora, USA
Elizaveta Smorodintseva, Russian Academy of Medical Sciences, National Influenza Center, Saint Petersburg, Russian Federation
Tomimasu Sunagawa, Infectious Disease Surveillance Center, National Institute of Infectious Diseases (NIID), Tokyo, Japan
Cristina Tecu, Laboratory of Respiratory Viral Infections Cantacuzino Institute, National Influenza Center (NIC), Bucharest, Romania
Almiro Tivane, Virus Isolation Laboratory, Surveillance Department, Instituto Nacional de Saúde, Ministério da Saúde, Maputo, Mozambique
Florette Treurnicht, National Institute for Communicable Diseases, Centre for Respiratory Diseases and Meningitis (Virology) NICD, Sandringham, South Africa
Niteit Wairagkar, Infectious Diseases, Global Health Program, Bill & Melinda Gates Foundation, Seattle, USA
Jila Yavarian, Virology Department, School of Public Health, Tehran University of Medical Sciences, Islamic Republic of Iran
Theodor Ziegler, Turku, Finland
<table>
<thead>
<tr>
<th>Name</th>
<th>Department</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terry Besselaar</td>
<td>WHO/HQ/HSE/GIP</td>
</tr>
<tr>
<td>Julia Fitzner</td>
<td>WHO/HQ/HSE/GIP</td>
</tr>
<tr>
<td>Ellah Frodeman</td>
<td>WHO/HQ/HSE/GIP</td>
</tr>
<tr>
<td>Christian Fuster</td>
<td>WHO/HQ/HSE/GIP</td>
</tr>
<tr>
<td>Siddhivinayak Hirve</td>
<td>WHO/HQ/HSE/GIP</td>
</tr>
<tr>
<td>Sandra Jackson</td>
<td>WHO/HQ/HSE/GIP</td>
</tr>
<tr>
<td>Ariadne L'Heveder</td>
<td>WHO/HQ/HSE/GIP</td>
</tr>
<tr>
<td>Awandha Mamahit</td>
<td>WHO/HQ/HSE/GIP</td>
</tr>
<tr>
<td>Piers Mook</td>
<td>EU/RGO/DCH/IRP</td>
</tr>
<tr>
<td>Karen Nahapetyan</td>
<td>WHO/EM/RGO/DCD</td>
</tr>
<tr>
<td>Vaseeharan</td>
<td>HQ/FWC/IVB/IVR</td>
</tr>
<tr>
<td>Sathiyaamoorthy</td>
<td></td>
</tr>
<tr>
<td>Katelijn Vandemaele</td>
<td>WHO/HQ/HSE/GIP</td>
</tr>
<tr>
<td>Wenqing Zhang</td>
<td>WHO/HQ/HSE/GIP</td>
</tr>
</tbody>
</table>
Declarations of Interest
The WHO Technical Meeting on Piloting RSV Surveillance based on the Global Influenza Surveillance and Response System, 28-30 June 2016 was organized by the Global Influenza Programme of WHO, with participation from National Influenza Centres, National epidemiologists, and international experts on RSV.

In accordance with WHO policy, all participants were required to complete the WHO form for Declaration of Interests for WHO Experts. James Nokes declared his involvement as an advisor without personal remuneration, in a meeting for RSV prevention organized by Medimmune in 2014. Harry Campbell declared consultancies and research grants from BMGF, US Fund for UNICEF, Sanofi for systematic review work on Clostridium difficile and meningitis, support for travel and participation in conferences organized by WHO, World Society for Pediatric Infectious Diseases, Salk Institute and Merieux Foundation. No other participant declared any personal current or recent (within the last 4 years) financial or other interests relevant to the subject of the meeting.

All declarations made were evaluated by the WHO Secretariat prior to the meeting. It was concluded that the interests declared did not conflict with the objectives of the meeting and that the above individuals could participate in full. At the start of the meeting the interests that had been declared were disclosed to all participants.